TrialESC heart failure2025

Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.

Francesco Fioretti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.